Matches in Wikidata for { <http://www.wikidata.org/entity/Q91550548> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q91550548 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91550548 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91550548 description "scientific article published on 03 April 2020" @default.
- Q91550548 description "wetenschappelijk artikel" @default.
- Q91550548 description "наукова стаття, опублікована 3 квітня 2020" @default.
- Q91550548 name "Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report" @default.
- Q91550548 name "Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report" @default.
- Q91550548 type Item @default.
- Q91550548 label "Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report" @default.
- Q91550548 label "Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report" @default.
- Q91550548 prefLabel "Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report" @default.
- Q91550548 prefLabel "Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report" @default.
- Q91550548 P1433 Q91550548-23E95D73-346E-46B1-B67D-8B80E2138BD1 @default.
- Q91550548 P1476 Q91550548-04408FAB-3D8D-4176-BC51-98C0DCCAB056 @default.
- Q91550548 P2093 Q91550548-424BCCD4-B71C-4A4A-8331-5A895699806E @default.
- Q91550548 P2093 Q91550548-4CD24B37-FB87-48F3-9586-5FF0BE432F33 @default.
- Q91550548 P2093 Q91550548-59DC6851-CB51-4CFD-9B81-92B688C81652 @default.
- Q91550548 P2093 Q91550548-7951D56B-6E54-489F-BCAF-6DDAB9E2C808 @default.
- Q91550548 P2093 Q91550548-834B0771-102D-4900-9D2E-31CD90C57AA0 @default.
- Q91550548 P2093 Q91550548-898ACD81-6A66-4C70-B695-0BFA67335CD3 @default.
- Q91550548 P2093 Q91550548-95390050-C061-48C2-8D22-A38DFE58C576 @default.
- Q91550548 P304 Q91550548-AF84E627-94EE-4632-8B65-2813BBC07833 @default.
- Q91550548 P31 Q91550548-012AA7A5-22AF-45E8-944E-A9A9F19D52C2 @default.
- Q91550548 P31 Q91550548-5695cea2-b2ab-4aec-bfbc-4a6e1b65a5ee @default.
- Q91550548 P356 Q91550548-5894545F-E826-418A-B20E-04630974E049 @default.
- Q91550548 P433 Q91550548-D5CC3744-6704-4ABC-85D7-13A57714A512 @default.
- Q91550548 P478 Q91550548-57FC2365-8E9E-4865-A8EE-A9B226B65CDA @default.
- Q91550548 P577 Q91550548-0B8868D4-D3FA-430F-8B3C-798EA32C6C28 @default.
- Q91550548 P698 Q91550548-8B18CC60-C0DE-4A02-9894-807516B736E9 @default.
- Q91550548 P921 Q91550548-41D1D68A-28AF-48D7-B290-42F178FC2651 @default.
- Q91550548 P921 Q91550548-B1210800-35C0-44BB-9735-BBF778D563F2 @default.
- Q91550548 P921 Q91550548-CBD1D3BB-1D05-4FC0-B670-C9A4B34D9FFA @default.
- Q91550548 P932 Q91550548-5845D1F7-E774-40EA-A8E3-F44B0195B63D @default.
- Q91550548 P356 S40360-020-00404-7 @default.
- Q91550548 P698 32245391 @default.
- Q91550548 P1433 Q27724429 @default.
- Q91550548 P1476 "Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report" @default.
- Q91550548 P2093 "Hanako Kuhara" @default.
- Q91550548 P2093 "Kazumi Nishino" @default.
- Q91550548 P2093 "Kei Kunimasa" @default.
- Q91550548 P2093 "Madoka Kimura" @default.
- Q91550548 P2093 "Motohiro Tamiya" @default.
- Q91550548 P2093 "Takako Inoue" @default.
- Q91550548 P2093 "Toru Kumagai" @default.
- Q91550548 P304 "26" @default.
- Q91550548 P31 Q13442814 @default.
- Q91550548 P31 Q2782326 @default.
- Q91550548 P356 "10.1186/S40360-020-00404-7" @default.
- Q91550548 P433 "1" @default.
- Q91550548 P478 "21" @default.
- Q91550548 P577 "2020-04-03T00:00:00Z" @default.
- Q91550548 P698 "32245391" @default.
- Q91550548 P921 Q13896859 @default.
- Q91550548 P921 Q7423598 @default.
- Q91550548 P921 Q7423600 @default.
- Q91550548 P932 "7118808" @default.